Completed PHASE3 INTERVENTIONAL 2-arm NCT00950768

Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients

GISMM2001: Melphalan 200 mg/m2 Versus Melphalan 100 mg/m2 in Newly Diagnosed Myeloma Patients: a Prospective, Multi-center Phase III Study

Sponsor: Azienda Ospedaliera San Giovanni Battista

Conditions Diagnosis Multiple Myeloma

Interventions Autologous transplantation

Updated 4 times since 2017 Last updated: Jul 31, 2009 Started: Feb 28, 2002 Primary completion: May 31, 2009 Completion: Jun 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00950768, this PHASE3 trial focuses on Diagnosis and Multiple Myeloma and remains completed. Sponsored by Azienda Ospedaliera San Giovanni Battista, it has been updated 4 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2017 — Jan 2021 [monthly]

Completed PHASE3

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Azienda Ospedaliera San Giovanni Battista

Data source: Azienda Ospedaliera San Giovanni Battista

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.